[Comment] Prioritising phosphatidylethanol to aid classification and treatment of steatotic liver disease

In 2023, a multinational consortium of liver experts introduced a revised nomenclature for steatotic liver disease.1 Steatotic liver disease was divided into metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease, and alcohol-related liver disease (ALD). A key gap in the old nomenclature was how to categorise patients whose clinical profile combined steatosis, metabolic risk factors, and ongoing alcohol consumption. In the updated framework, individuals who meet MASLD criteria and consume alcohol within the range of 140–350 g per week for women and 210–420 g per week for men are placed in a new hybrid category: metabolic dysfunction and ALD (MetALD).